Intravenous Immunoglobulin for Congenital Parvovirus Myocarditis

Yonatan Kurland; Ranjit I. Kylat; Drew C. Johnson; Brent J. Barber; Alan D. Bedrick; Mohammad Y. Bader

doi:10.1055/s-0037-1620249

Journal of Pediatric Infectious Diseases, Inhaltsverzeichnis

J Pediatr Infect Dis 2020; 15(01): 053-056
DOI: 10.1055/s-0037-1620249

Case Report

Georg Thieme Verlag KG Stuttgart · New York

Intravenous Immunoglobulin for Congenital Parvovirus Myocarditis

Yonatan Kurland

¹Department of Pediatrics, Arizona Health Sciences Center, The University of Arizona, Tucson, Arizona, United States

,

Ranjit I. Kylat

¹Department of Pediatrics, Arizona Health Sciences Center, The University of Arizona, Tucson, Arizona, United States

²Section of Neonatal-Perinatal Medicine and Developmental Biology, Arizona Health Sciences Center, The University of Arizona, Tucson, Arizona, United States

,

Drew C. Johnson

¹Department of Pediatrics, Arizona Health Sciences Center, The University of Arizona, Tucson, Arizona, United States

,

Brent J. Barber

¹Department of Pediatrics, Arizona Health Sciences Center, The University of Arizona, Tucson, Arizona, United States

³Section of Pediatric Cardiology, Arizona Health Sciences Center, The University of Arizona, Tucson, Arizona, United States

,

Alan D. Bedrick

¹Department of Pediatrics, Arizona Health Sciences Center, The University of Arizona, Tucson, Arizona, United States

²Section of Neonatal-Perinatal Medicine and Developmental Biology, Arizona Health Sciences Center, The University of Arizona, Tucson, Arizona, United States

,

Mohammad Y. Bader

¹Department of Pediatrics, Arizona Health Sciences Center, The University of Arizona, Tucson, Arizona, United States

²Section of Neonatal-Perinatal Medicine and Developmental Biology, Arizona Health Sciences Center, The University of Arizona, Tucson, Arizona, United States

› Institutsangaben

Abstract

Congenital parvovirus infection has a diverse presentation ranging from asymptomatic infants to intrauterine demise secondary to red cell aplasia or myocarditis. Treatment is aimed at correcting anemia with intrauterine and postnatal transfusions. We report a case of fetal hydrops with severe atrioventricular regurgitation and myocardial dysfunction secondary to parvovirus infection in a preterm infant. Myocarditis and myocardial dysfunction responded to immunoglobulin administration.

Keywords

congenital parvovirus infection - myocarditis - immunoglobulin

Volltext

Referenzen

References
1 Adler SP, Koch WC. Human parvovirus. In: Remington JS, Klein JO. , eds. Infectious Diseases of the Fetus and Newborn Infant. 8th ed. Philadelphia, PA: Elsevier; 2016: 866-893
2 Barton LL, Lax D, Shehab ZM, Keith JC. Congenital cardiomyopathy associated with human parvovirus B19 infection. Am Heart J 1997; 133 (01) 131-133
3 Selbing A, Josefsson A, Dahle LO, Lindgren R. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet 1995; 345 (8950): 660-661
4 Matsuda H, Sakaguchi K, Shibasaki T, Takahashi H, Kawakami Y, Furuya K. Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med 2005; 33 (06) 561-563
5 Lejeune A, Cremer M, von Bernuth H, Edelmann A, Modrow S, Bührer C. Persistent pure red cell aplasia in dicygotic twins with persistent congenital parvovirus B19 infection-remission following high dose intravenous immunoglobulin. Eur J Pediatr 2014; 173 (12) 1723-1726
6 Nadimpalli SS, Miller RS, Kamath VM. , et al. Congenital parvovirus B19 infection: persistent viremia and red blood cell aplasia. Open Forum Infect Dis 2015; 2 (02) ofv049 . Doi: 10.1093/ofid/ofv049
7 Brown KE, Green SW, Antunez de Mayolo J. , et al. Congenital anaemia after transplacental B19 parvovirus infection. Lancet 1994; 343 (8902): 895-896
8 Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 2004; 24 (07) 513-518
9 Kishimoto C, Abelmann WH. In vivo significance of T cells in the development of Coxsackievirus B3 myocarditis in mice. Immature but antigen-specific T cells aggravate cardiac injury. Circ Res 1990; 67 (03) 589-598
10 George J, Barshack I, Malka E. , et al. The effect of intravenous immunoglobulins on the progression of experimental autoimmune myocarditis in the rat. Exp Mol Pathol 2001; 71 (01) 55-62
11 Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340 (03) 227-228
12 Stouffer GA, Sheahan RG, Lenihan DJ, Patel P, Lenihan DJ. The current status of immune modulating therapy for myocarditis: a case of acute parvovirus myocarditis treated with intravenous immunoglobulin. Am J Med Sci 2003; 326 (06) 369-374
13 Dennert R, Velthuis S, Schalla S. , et al. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther 2010; 15 (02) 193-201
14 Crabol Y, Terrier B, Rozenberg F. , et al; Groupe d'experts de l'Assistance Publique-Hôpitaux de Paris. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis 2013; 56 (07) 968-977